1. An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases
- Author
-
Fan Wang, Wen Zhang, Jianhua Li, Min Wu, Zhenghong Yuan, Peng Xiuhua, Jieliang Chen, Junyu Lin, Cuncun Chen, and Ye Zheng
- Subjects
HBsAg ,Hepatitis B virus ,Genetic Vectors ,Genome, Viral ,Biology ,medicine.disease_cause ,Antiviral Agents ,Virus ,Cell Line ,chemistry.chemical_compound ,Mice ,Viral Proteins ,Hepatitis B, Chronic ,Drug Discovery ,Genetics ,medicine ,Animals ,Humans ,Molecular Biology ,Pharmacology ,Transcription activator-like effector nuclease ,Deoxyribonucleases ,virus diseases ,Interferon-alpha ,cccDNA ,Virology ,Molecular biology ,digestive system diseases ,HBcAg ,Disease Models, Animal ,HBeAg ,chemistry ,Molecular Medicine ,Original Article ,DNA, Circular ,DNA ,Plasmids ,Protein Binding - Abstract
The hepatitis B virus (HBV) is a DNA virus that can cause chronic hepatitis B (CHB) in humans. Current therapies for CHB infection are limited in efficacy and do not target the pre-existing viral genomic DNA, which are present in the nucleus as a covalently closed circular DNA (cccDNA) form. The transcription activator-like (TAL) effector nucleases (TALENs) are newly developed enzymes that can cleave sequence-specific DNA targets. Here, TALENs targeting the conserved regions of the viral genomic DNA among different HBV genotypes were constructed. The expression of TALENs in Huh7 cells transfected with monomeric linear full-length HBV DNA significantly reduced the viral production of HBeAg, HBsAg, HBcAg, and pgRNA, resulted in a decreased cccDNA level and misrepaired cccDNAs without apparent cytotoxic effects. The anti-HBV effect of TALENs was further demonstrated in a hydrodynamic injection-based mouse model. In addition, an enhanced antiviral effect with combinations of TALENs and interferon-α (IFN-α) treatment was observed and expression of TALENs restored HBV suppressed IFN-stimulated response element-directed transcription. Taken together, these data indicate that TALENs can specifically target and successfully inactivate the HBV genome and are potently synergistic with IFN-α, thus providing a potential therapeutic strategy for treating CHB infection.
- Published
- 2013